Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8855 | 0.68 | GAA (0.48) | GAAMAPT | |
| SCHEMBL20958405 | 0.65 | GAA (0.50) | GAAMAPT | |
| SCHEMBL55652 | 0.64 | GAA (0.43) | GAAMAPT | |
| Bromide SCHEMBL3719757 | 0.64 | GAA (0.48) | GAAMAPT | |
| SCHEMBL447768 | 0.64 | GAA (0.33) | GAAMAPT | |
| SCHEMBL34259 | 0.64 | GAA (0.48) | GAAMAPT | |
| Iminostilbene SCHEMBL29926907 | 0.63 | MAPT (1.00) | GAAMAPT | |
| SCHEMBL3531045 | 0.63 | — | — | |
| Iminostilbene SCHEMBL75288 | 0.63 | MAPT (1.00) | GAAMAPT | |
| SCHEMBL8654087 | 0.62 | GAA (0.46) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872490-A1 | ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | claimed |
| WO-2014009495-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | claimed |
| WO-2010056496-A1 | AZEPINONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | claimed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | claimed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2872490-A1 | ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009495-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| WO-2010056496-A1 | AZEPINONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-0463969-B1 | New compounds of 4-aminobutyric acid, process for their preparation and pharmaceutical preparations containing them | ADIR (FR) | 1995-02-08 | — | — | EP | disclosed |
| EP-0463969-A1 | New compounds of 4-aminobutyric acid, process for their preparation and pharmaceutical preparations containing them | ADIR ET COMPAGNIE (FR) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | GAA 4788/4885MAPT 4271/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | GAA 4788/4885MAPT 4271/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | GAA 2113/4885MAPT 4302/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | GAA 4829/4885MAPT 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.